TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23530022

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study: 21272454

Group type: EXPERIMENTAL
Intervention: Interferon a‐1b (50mug I. M., qod)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Interferon a‐1b combined with lamivudine (100 mg, P.O., q.d. for 6-12 months or longer)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Interferon a‐1b combined with lamivudine
Number of subjects: 111
Study: 19637345

Group type: EXPERIMENTAL
Intervention: Home-based walking intervention (exercise)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 126
Study: 17605253

Group type: EXPERIMENTAL
Intervention: Artificial dermis and recombinant bFGF2 spray, applied twice a day after immersion bath, dressing changed every other day or every 2 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Monolayer gauze wetted with povidone iodine
Number of subjects: 56
Study: 15127239

Group type: EXPERIMENTAL
Intervention: Evaluation of serum tumour markers (CA 15.3, CEA, TPA, TPS, Cyfra 21.1) for monitoring therapeutic response.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of serum markers for diagnosis of recurrent disease.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective randomised studies on serum markers for earlier therapeutic interventions.
Number of subjects: 0
Study: 11483170

Group type: EXPERIMENTAL
Intervention: Cognitive task involving sequential learning, explicit processing, and working memory
Number of subjects: 0
Study: 9783295

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide (N2O)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100% oxygen (O2)
Number of subjects: 20
Study: 7522906

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 x 10(6) KI units intravenous bolus and 0.5 x 10(6) KI units h‐1 plus 2 x 10(6) KI units into pump prime)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aprotinin added to pump prime (2 x 10(6) KI units)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient group (aprotinin 10(6) KI units intravenous bolus plus 10(6) KI units added to pump prime)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (0.9 per cent saline placebo)
Number of subjects: 100
Study: 2839632

Group type: EXPERIMENTAL
Intervention: Etoposide (EVAC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: VAC (vincristine, doxorubicin, cyclophosphamide)
Number of subjects: 136
Study: 31672793

Group type: EXPERIMENTAL
Intervention: Extended dialysis hours
Number of subjects: 200
Study: 29745114

Group type: EXPERIMENTAL
Intervention: Gelatin tannate (GT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25698173

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova therapy, 2500 ova orally every second week for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 10
Study: 22963881

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 99
Study: 21572019

Group type: COMPARATOR
Intervention: External counterpulsation (ECP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 20
Study: 17922185

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (exemestane and letrozole)
Number of subjects: 100
Study: 16820790

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (750 mg/m2, 13 pulses in 2 years) combined with oral prednisone (CY)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg/day in 2 years) combined with intravenous pulses of methylprednisolone (3 x 3 pulses of 1000 mg) and oral prednisone (AZA)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 87
Study: 12637117

Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS 35.0 microg/h
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS 52.5 microg/h
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS 70.0 microg/h
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 10710845

Group type: EXPERIMENTAL
Intervention: Mailings-only intervention (8 relapse-prevention booklets mailed over 1 year)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Control condition (non-mailing conditions)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Combined conditions (both interventions)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Hot-line-only intervention (12-month access to a telephone hot line)
Number of subjects: 584
Study: 9181182

Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 180

Group type: COMPARATOR
Intervention: IUD
Number of subjects: 180
Study: 1492307

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both treatment modes
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Algometer
Number of subjects: 110
Study: 2993690

Group type: EXPERIMENTAL
Intervention: SBT/CPZ (0.5 g SBT + 0.5 g CPZ, 2 times/day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: CZX (1.0 g, 2 times/day)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: SBT/CPZ
Number of subjects: 137

Group type: COMPARATOR
Intervention: CZX
Number of subjects: 137
Study: 31729647

Group type: EXPERIMENTAL
Intervention: Intensive therapy group (target serum UA level ≥ 4.0 mg/dL, < 5.0 mg/dL)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard therapy group (serum UA level ≥ 6.0 mg/dL, < 7.0 mg/dL)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Intensive therapy group
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard therapy group
Number of subjects: 370
Study: 29453772

Group type: EXPERIMENTAL
Intervention: Intrasulcular incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paramarginal incision
Number of subjects: 60
Study: 28065445

Group type: EXPERIMENTAL
Intervention: Colchicine (1mg once daily for 1 month plus optimal medical treatment)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (optimal medical treatment only)
Number of subjects: 44
Study: 26278118

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24140959

Group type: EXPERIMENTAL
Intervention: Frequency Doubling Technology (FDT) perimetry
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 20
Study: 21493743

Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisolone, azathioprine, heparin‐warfarin, and dipyridamole)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control therapy (heparin‐warfarin and dipyridamole)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 78
Study: 19110789

Group type: EXPERIMENTAL
Intervention: TITANOX-coated stent
Number of subjects: 425

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 425
Study: 17133785

Group type: EXPERIMENTAL
Intervention: Pioglitazone combined with metformin (1500 mg/day increasing to 3000 mg/day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Rosiglitazone combined with metformin (1500 mg/day increasing to 3000 mg/day)
Number of subjects: 103
Study: 15612454

Group type: EXPERIMENTAL
Intervention: Poloxamer 188 (n = 4)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 9
Study: 11478141

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy
Number of subjects: 0
Study: 9252771

Group type: EXPERIMENTAL
Intervention: Hydrocolloid + PVP-I treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hydrocolloid treatment
Number of subjects: 15
Study: 8389339

Group type: EXPERIMENTAL
Intervention: High fat meal (30 g margarine; 1327 kJ (317 kcal))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low fat meal (301 kJ (72 kcal))
Number of subjects: 15
Study: 3040455

Group type: COMPARATOR
Intervention: ACTH 4-10 (0 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (0.1 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (1.0 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (10 mg)
Number of subjects: 12
Study: 30003102

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment for 36 sessions
Number of subjects: 242

Group type: COMPARATOR
Intervention: Escitalopram treatment
Number of subjects: 242
Study: 26852398

Group type: EXPERIMENTAL
Intervention: UVB treatment (n=26)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cholecalciferol injection (n=20)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (n=27)
Number of subjects: 73
Study: 23837834

Group type: EXPERIMENTAL
Intervention: Applanation Resonance Tonometry (ART)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Comparison of ART and GAT
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intra-examiner variability
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Influence of Central Corneal Thickness (CCT)
Number of subjects: 153
Study: 23131064

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment plus usual care
Number of subjects: 165

Group type: COMPARATOR
Intervention: Supportive listening plus usual care
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 165
Study: 19774349

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No zinc supplementation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 38
Study: 18337049

Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Videophone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nurse perceptions
Number of subjects: 28
Study: 15562251

Group type: EXPERIMENTAL
Intervention: CHO+PRO+Leu
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 8
Study: 11182217

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 1290
Study: 9018611

Group type: EXPERIMENTAL
Intervention: Grip exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Push-up exercise
Number of subjects: 14
Study: 7877434

Group type: EXPERIMENTAL
Intervention: Alpha interferon treatment
Number of subjects: 24
Study: 3236746

Group type: EXPERIMENTAL
Intervention: Tono-Pen (TP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Goldmann tonometer (GM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Tono-Pen (TP) and Goldmann tonometer (GM)
Number of subjects: 108
Study: 30276771

Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong intervention for three months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 28959158

Group type: EXPERIMENTAL
Intervention: Pre-workout supplement (PWS) - Reckless™
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PBO) - maltodextrin and glycine
Number of subjects: 30
Study: 23089176

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of pregabalin, cetirizine, and pheniramine maleate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antihistaminic combination (cetirizine with pheniramine maleate)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (vit. B comp.)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Massage with coconut oil
Number of subjects: 80
Study: 21647425

Group type: EXPERIMENTAL
Intervention: Polypill (aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg and simvastatin 20 mg)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 19665601

Group type: EXPERIMENTAL
Intervention: lasofoxifene (0.25 mg/d)
Number of subjects: 51
Study: 16734920

Group type: EXPERIMENTAL
Intervention: Carer-held records (CHR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no CHR)
Number of subjects: 84
Study: 15324987

Group type: EXPERIMENTAL
Intervention: Computer-based interactive training program (CBITP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional training (written instructions)
Number of subjects: 64
Study: 11388226

Group type: COMPARATOR
Intervention: Medtronic Freestyle valve (group F)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Homograft (group H)
Number of subjects: 37
Study: 9140673

Group type: EXPERIMENTAL
Intervention: Bunazosin (6 and 12 mg once daily for 12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Atenolol (50 and 100 mg once daily for 12 weeks)
Number of subjects: 32
Study: 7952624

Group type: EXPERIMENTAL
Intervention: Breathing 60% O2 during exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: Breathing room air (RA)
Number of subjects: 7
Study: 3136279

Group type: EXPERIMENTAL
Intervention: naaga (magnesium salt of N‐acetyl aspartyl glutamic acid‐rhinaaxia)
Number of subjects: 91

Group type: COMPARATOR
Intervention: disodium cromoglycate (LOMUPREN)
Number of subjects: 91
Study: 31747840

Group type: EXPERIMENTAL
Intervention: Nintedanib (Ofev™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30852481

Group type: EXPERIMENTAL
Intervention: Fructus akebiae extract combined with ursodeoxycholic acid (UDCA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: ursodeoxycholic acid (UDCA)
Number of subjects: 180
Study: 29423403

Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid (1 gr. tablet given 12 hours and 1 hour before surgery)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 34
Study: 26699529

Group type: EXPERIMENTAL
Intervention: Cefepime (50 mg/kg up to 2 g single dose perioperative intravenous infusion)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Ceftriaxone (50 mg/kg up to 2 g single dose perioperative intravenous infusion)
Number of subjects: 230
Study: 23322359

Group type: EXPERIMENTAL
Intervention: Cued recall with fewer categories (2 categories)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued recall with more categories (24 categories)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rote repetition with fewer categories (2 categories)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive imagery with fewer categories (2 categories)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free recall with fewer categories (2 categories)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued recall with more categories (20 categories)
Number of subjects: 0
Study: 21214368

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (685 nm, energy density 10 J/cm(2)) in addition to conventional therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study: 18156492

Group type: EXPERIMENTAL
Intervention: t(9;22)/BCR/ABL1
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: other unfavorable karyotypes
Number of subjects: 200

Group type: COMPARATOR
Intervention: normal diploid group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: miscellaneous group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: age
Number of subjects: 200
Study: 21254854

Group type: EXPERIMENTAL
Intervention: PUVA therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Topical steroids
Number of subjects: 88
Study: 15620772

Group type: EXPERIMENTAL
Intervention: Chesterfield stent for palatal endosseous implant placement
Number of subjects: 0
Study: 12883396

Group type: EXPERIMENTAL
Intervention: Endotracheal Tube (ETT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 14
Study: 9797758

Group type: EXPERIMENTAL
Intervention: High dose inhaled beclomethasone dipropionate (BDP) 500 micrograms three times daily for two months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High dose inhaled beclomethasone dipropionate (BDP)
Number of subjects: 34
Study: 7544851

Group type: EXPERIMENTAL
Intervention: Consolidation Arm A: cytosine arabinoside 200 mg/m2 daily for 7 days and daunorubicin 45 mg/m2 daily for 3 days for three courses
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Consolidation Arm B: one course as in Arm A followed by amsacrine 120 mg/m2 daily for 5 days and a 5-day continuous infusion of azacytidine 150 mg/m2/day
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Consolidation Arm C: thioguanine and cytosine arabinoside 100 mg/m2 every 12 h and daunorubicin 10 mg/m2 daily for 5 days for three courses followed by four maintenance courses of cytosine arabinoside 100 mg/m2 daily for 5 days and daunorubicin 45 mg/m2 for 2 days every 13 weeks
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy with the same or different drugs used in induction
Number of subjects: 398
Study: 2910220

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metergoline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1207432

Group type: EXPERIMENTAL
Intervention: Experimental group (fatigued)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not fatigued)
Number of subjects: 60
Study: 30158516

Group type: EXPERIMENTAL
Intervention: Very high-protein and low-carbohydrate enteral nutrition formula
Number of subjects: 12

Group type: COMPARATOR
Intervention: Very high-protein and higher-carbohydrate formula
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin response
Number of subjects: 12
Study: 28558160

Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (RYGB+EX)
Number of subjects: 96

Group type: COMPARATOR
Intervention: lifestyle educational classes (RYGB)
Number of subjects: 96
Study: 25850463

Group type: EXPERIMENTAL
Intervention: Anapen
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: EpiPen
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Auvi-Q
Number of subjects: 158

Group type: COMPARATOR
Intervention: Other devices (not specified)
Number of subjects: 158
Study: 22845185

Group type: EXPERIMENTAL
Intervention: Subcutaneous Triptorelin acetate (0.1 mg/m(2), to a maximum of 0.1 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intravenous GnRH 100 μg
Number of subjects: 46
Study: 21527478

Group type: EXPERIMENTAL
Intervention: Parent testimonials
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Expert testimonials
Number of subjects: 143

Group type: COMPARATOR
Intervention: No testimonial condition
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Expert testimonials framed in fear context
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Expert testimonials framed in non-fear context
Number of subjects: 143
Study: 18443672

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) tramadol 200 mg, titrated to a maximum of 400 mg per day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sustained-release (SR) diclofenac 75 mg, titrated to a maximum of 100 mg once daily or 75 mg twice a day
Number of subjects: 97
Study: 17059314

Group type: EXPERIMENTAL
Intervention: Nostalgia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood and loneliness triggers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nostalgic experiences
Number of subjects: 0
Study: 14616354

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 10
Study: 11475496

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 1102
Study: 9130360

Group type: COMPARATOR
Intervention: Traditional didactic lecture mode (control group)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Role plays and audiotaped feedback
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Role plays with peer feedback
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Video feedback
Number of subjects: 219
Study: 1571904

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX) with total doses of 6720, 7200, 7680, and 8160 cGy, using 120 cGy twice daily, 5 days per week.
Number of subjects: 233

Group type: COMPARATOR
Intervention: Delays of 5 days or more in treatment.
Number of subjects: 233
Study: 6463064

Group type: EXPERIMENTAL
Intervention: 1 g cephradine
Number of subjects: 48

Group type: COMPARATOR
Intervention: 500 mg flucloxacillin plus 500 mg ampicillin
Number of subjects: 48
Study: 29582946

Group type: EXPERIMENTAL
Intervention: High dose cannabis (6 patients)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low dose cannabis (8 patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Active placebo (6 patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (7 patients)
Number of subjects: 27
Study: 27394691

Group type: EXPERIMENTAL
Intervention: Slow loaded sit-to-stand exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Self-paced loaded sit-to-stand exercise
Number of subjects: 16
Study: 26441181

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 199

Group type: COMPARATOR
Intervention: Colon resection
Number of subjects: 199
Study: 25016757

Group type: EXPERIMENTAL
Intervention: Narrowband UVB therapy for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythmogenic strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suberythmogenic strategy
Number of subjects: 0
Study: 20859298

Group type: EXPERIMENTAL
Intervention: Unprocessed Fabuless
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Processed Fabuless
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Self-reported appetite scores
Number of subjects: 24